(NYSE: RCUS) Arcus Biosciences's forecast annual revenue growth rate of -1% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.08%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.19%.
Arcus Biosciences's revenue in 2026 is $247,000,000.On average, 13 Wall Street analysts forecast RCUS's revenue for 2026 to be $12,100,360,967, with the lowest RCUS revenue forecast at $859,897,405, and the highest RCUS revenue forecast at $29,613,813,705. On average, 13 Wall Street analysts forecast RCUS's revenue for 2027 to be $20,677,649,561, with the lowest RCUS revenue forecast at $0, and the highest RCUS revenue forecast at $46,651,314,483.
In 2028, RCUS is forecast to generate $30,212,984,200 in revenue, with the lowest revenue forecast at $9,818,624,455 and the highest revenue forecast at $77,749,265,984.